Increased all-cause and cancer mortality in HTLV-II infection.

摘要: Human T-lymphotropic virus (HTLV) types I and II are human retroviruses that establish lifelong chronic infection. They distributed worldwide endemic in central Africa, southern Japan, the Caribbean South America, where prevalence of infection can be as high 5-10% certain populations.1, 2 HTLV-I is mainly transmitted through mother-to-child routes HTLV-II parenteral routes, particularly injection drug use. Although majority infected individuals remain asymptomatic, cause adult T-cell leukemia/lymphoma, HTLV-associated myelopathy, opportunistic infections, such Strongyloides stercoralis.3 has a different spectrum pathogenesis than HTLV-I,4 but also been linked with myelopathy,5 addition to respiratory infections inflammatory conditions.6 Few studies have examined impact on survival. In study an urban community-based cohort Guinea-Bissau, was associated 2-fold increased mortality rate.7 another patients outpatient clinics those receiving annual health check-ups at hospital southwestern 1.3-fold increase all-cause mortality, not general cancer risk.8 number unique populations, including atomic-bomb survivors Nagasaki, Japan9 leprosy Congo.10 An earlier report from our own large prospective former blood donors analyzed 45 deaths found risk death among donors.11 showed elevated death, though it significant. Other shown no effect or even protective survival.12-15 However, these were carried out subjects coexisting HIV use, may limited by competing mortality. Since report, accumulated many more person-years follow-up, aged. The includes both subjects, allowing comparison groups seronegative controls. Since recruited donors, advantage morbidity After 18 years since inception cohort, we therefore decided re-evaluate survival individuals.